サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1635852

網膜芽細胞腫治療市場レポート：タイプ別、治療タイプ別、病期別、用途別、地域別、2025-2033年

Retinoblastoma Treatment Market Report by Type, Treatment Type, Type of Staging, Application, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 142 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
網膜芽細胞腫治療市場レポート：タイプ別、治療タイプ別、病期別、用途別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

網膜芽細胞腫治療市場の世界市場規模は2024年に30億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに41億米ドルに達し、2025～2033年の成長率（CAGR）は3.52％になると予測しています。眼科治療に対する医療支出の大幅な増加、副作用の少ない治療法の研究開発（R&D）活動への投資の増加、健康意識の高まりなどが市場を牽引する主な要因です。

網膜芽細胞腫は最も一般的ながんの1つで、一般に小児では5歳以前に発症します。網膜芽細胞腫の症状には、猫の眼反射（cat's eye reflex）または白斑（leukocoria）と呼ばれる瞳孔の白濁があります。網膜芽細胞腫の治療には、さまざまなドラッグデリバリーや化学療法があり、網膜芽細胞腫は初期段階では治癒可能であるため、短期的には一定の効果が得られます。1回目または2回目の化学療法サイクルに続いて、腫瘍の縮小度や眼球内の位置に応じて、さまざまな局所治療を適用することができます。さまざまな治療法を組み合わせることが、最も成功する網膜芽細胞腫の治療法です。手術は網膜から腫瘍を完全に除去するため、恒久的な網膜芽細胞腫の治療法です。網膜芽細胞腫の詳細な診断には、超音波検査、CTスキャン、MRI、X線検査、骨スキャンなど、さまざまな画像検査があります。

網膜芽細胞腫治療市場動向：

眼科治療に対する医療支出の大幅な増加が市場を牽引する重要な要因です。この背景には、若年層における網膜芽細胞腫の増加があります。これに伴い、より副作用の少ない、より効率的な新しい治療戦略に焦点を当てた研究開発（R&D）活動への投資が増加しており、市場に弾みをつけています。さらに、さまざまな種類のがんに対する認識が高まり、診断率や治療率が高まっていることも、大きな成長促進要因となっています。しかし、様々な網膜芽細胞腫治療薬が入手できないことと、厳しい薬事規制が市場の成長抑制要因となっています。これとは反対に、新薬の上市につながる製品承認の数が増加していることは、市場に明るい見通しをもたらしています。これに加えて、網膜芽細胞腫の再発率の増加も、網膜芽細胞腫治療市場に有利な機会を生み出しています。市場はさらに、提携や共同研究、合併・買収（M&A）など、主要な支払者が実施するさまざまな有機的成長戦略によって推進されています。これとは別に、強力なパイプライン医薬品の存在と臨床試験件数の増加が市場の成長を後押ししています。その他、急速な都市化、可処分所得水準の上昇、がん研究の大幅な成長、世界各地の医療インフラの改善なども市場に寄与しています。

本レポートで扱う主な質問

  • 世界の網膜芽細胞腫治療市場はこれまでどのように推移し、今後どのように推移していくのか？
  • 世界の網膜芽細胞腫治療市場における促進要因、抑制要因、機会は何か？
  • 主要な地域市場とは？
  • 最も魅力的な網膜芽細胞腫治療市場はどの国か？
  • タイプ別の市場内訳は？
  • 治療タイプ別の市場内訳は？
  • 病期別の市場内訳は？
  • 用途別の市場内訳は？
  • 世界の網膜芽細胞腫治療市場の競合構造は？
  • 網膜芽細胞腫治療市場の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の網膜芽細胞腫治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 非遺伝性網膜芽細胞腫
    • 市場動向
    • 市場予測
  • 遺伝性網膜芽細胞腫
    • 市場動向
    • 市場予測

第7章 市場内訳：治療タイプ別

  • 手術
    • 市場動向
    • 市場予測
  • 放射線治療
    • 市場動向
    • 市場予測
  • レーザー治療（光凝固術）
    • 市場動向
    • 市場予測
  • 凍結療法
    • 市場動向
    • 市場予測
  • 温熱療法
    • 市場動向
    • 市場予測
  • 化学療法
    • 市場動向
    • 市場予測
  • 眼動脈注入化学療法
    • 市場動向
    • 市場予測
  • 高用量化学療法と幹細胞移植
    • 市場動向
    • 市場予測

第8章 市場内訳：病期別

  • 眼球内網膜芽細胞腫
    • 市場動向
    • 市場予測
  • 眼球外網膜芽細胞腫
    • 市場動向
    • 市場予測

第9章 市場内訳：用途別

  • 病院
    • 市場動向
    • 市場予測
  • がん研究所
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bristol Myers Squibb Company
    • Pfizer Inc.
    • Teva Canada Limited（Teva Pharmaceutical Industries Ltd.）
図表

List of Figures

  • Figure 1: Global: Retinoblastoma Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Retinoblastoma Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Retinoblastoma Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Retinoblastoma Treatment Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Retinoblastoma Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 6: Global: Retinoblastoma Treatment Market: Breakup by Type of Staging (in %), 2024
  • Figure 7: Global: Retinoblastoma Treatment Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Retinoblastoma Treatment Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Retinoblastoma Treatment (Non-Hereditary Retinoblastoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Retinoblastoma Treatment (Non-Hereditary Retinoblastoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Retinoblastoma Treatment (Hereditary Retinoblastoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Retinoblastoma Treatment (Hereditary Retinoblastoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Retinoblastoma Treatment (Surgery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Retinoblastoma Treatment (Surgery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Retinoblastoma Treatment (Radiation Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Retinoblastoma Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Retinoblastoma Treatment (Laser Therapy (Photocoagulation)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Retinoblastoma Treatment (Laser Therapy (Photocoagulation)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Retinoblastoma Treatment (Cryotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Retinoblastoma Treatment (Cryotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Retinoblastoma Treatment (Thermotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Retinoblastoma Treatment (Thermotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Retinoblastoma Treatment (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Retinoblastoma Treatment (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Retinoblastoma Treatment (Opthalmic Artery Infusion Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Retinoblastoma Treatment (Opthalmic Artery Infusion Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Retinoblastoma Treatment (High-Dose Chemotherapy and Stem Cell Transplant) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Retinoblastoma Treatment (High-Dose Chemotherapy and Stem Cell Transplant) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Retinoblastoma Treatment (Intraocular Retinoblastoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Retinoblastoma Treatment (Intraocular Retinoblastoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Retinoblastoma Treatment (Extraocular Retinoblastoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Retinoblastoma Treatment (Extraocular Retinoblastoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Retinoblastoma Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Retinoblastoma Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Retinoblastoma Treatment (Cancer Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Retinoblastoma Treatment (Cancer Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Retinoblastoma Treatment (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Retinoblastoma Treatment (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: North America: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: North America: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: United States: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: United States: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Canada: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Canada: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Asia-Pacific: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Asia-Pacific: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: China: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: China: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Japan: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Japan: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: India: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: India: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: South Korea: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: South Korea: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Australia: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Australia: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Indonesia: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Indonesia: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Others: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Others: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Europe: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Europe: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Germany: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Germany: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: France: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: France: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: United Kingdom: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: United Kingdom: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Italy: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Italy: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Spain: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Spain: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Russia: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Russia: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Latin America: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Latin America: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Brazil: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Brazil: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Mexico: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Mexico: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Middle East and Africa: Retinoblastoma Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Middle East and Africa: Retinoblastoma Treatment Market: Breakup by Country (in %), 2024
  • Figure 87: Middle East and Africa: Retinoblastoma Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Global: Retinoblastoma Treatment Industry: Drivers, Restraints, and Opportunities
  • Figure 89: Global: Retinoblastoma Treatment Industry: Value Chain Analysis
  • Figure 90: Global: Retinoblastoma Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Retinoblastoma Treatment Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Retinoblastoma Treatment Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Retinoblastoma Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 4: Global: Retinoblastoma Treatment Market Forecast: Breakup by Type of Staging (in Million USD), 2025-2033
  • Table 5: Global: Retinoblastoma Treatment Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Retinoblastoma Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Retinoblastoma Treatment Market: Competitive Structure
  • Table 8: Global: Retinoblastoma Treatment Market: Key Players
目次
Product Code: SR112025A6732

The global retinoblastoma treatment market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.1 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. A considerable rise in healthcare expenditure for ophthalmic treatment procedures, increasing investments in research and development (R&D) activities on therapies with lower side effects, and the increasing health consciousness represent some of the key factors driving the market.

Retinoblastoma is one of the most common cancers that generally develops before the age of 5 in children. Some of the symptoms of retinoblastoma include a white appearance in the pupil called cat's eye reflex or leukocoria. Retinoblastoma treatment can include a variety of drug delivery and chemotherapy techniques that provide some benefits in the short term since retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, different focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. A combination of different treatment methods is the most successful retinoblastoma treatment option. Surgery is the permanent retinoblastoma treatment option as it removes the tumor thoroughly from the retina. There are a variety of imaging tests available for a detailed diagnosis of retinoblastoma, including ultrasound, CT-scan, MRI, X-ray, and bone scan.

Retinoblastoma Treatment Market Trends:

A considerable rise in healthcare expenditure for ophthalmic treatment procedures is a significant factor driving the market. This can be attributed to the rising incidences of retinoblastoma among the younger population. In line with this, increasing investments in research and development (R&D) activities focusing on newer, more efficient therapeutic strategies with lesser associated side effects is providing an impetus to the market. Moreover, the growing awareness regarding different type of cancers resulting in higher diagnosis and treatment rates are also acting as a significant growth-inducing factor. However, the lack of availability of various retinoblastoma treatment drugs, along with stringent drug regulations, are acting as a growth-restraining factor for the market. On the contrary, the increasing number of product approvals leading to the launches of new drug variants is creating a positive outlook for the market. Besides this, the growing rates of recurrence of retinoblastoma are also creating lucrative opportunities in the retinoblastoma treatment market. The market is further propelled by various organic growth strategies undertaken by key payers, such as partnerships and collaborations, and merger and acquisitions (M&As). Apart from this, the presence of strong pipeline drugs, along with the augmenting number of clinical trials, are fueling the market growth. Some of the other factors contributing to the market include rapid urbanization, inflating disposable income levels, considerable growth in cancer research, and improvements in medical infrastructure across the globe.

Key Market Segmentation:

Type Insights:

  • Non-Hereditary Retinoblastoma
  • Hereditary Retinoblastoma

Treatment Type Insights:

  • Surgery
  • Radiation Therapy
  • Laser Therapy (Photocoagulation)
  • Cryotherapy
  • Thermotherapy
  • Chemotherapy
  • Opthalmic Artery Infusion Chemotherapy
  • High-Dose Chemotherapy and Stem Cell Transplant

Type of Staging Insights:

  • Intraocular Retinoblastoma
  • Extraocular Retinoblastoma

Application Insights:

  • Hospitals
  • Cancer Institutes
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for retinoblastoma treatment. Some of the factors driving the Asia Pacific retinoblastoma treatment market include the growing rates of recurrence of retinoblastoma, higher diagnosis and treatment rates due to the increasing awareness regarding different types of cancers, the presence of several key players in the region, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global retinoblastoma treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol Myers Squibb Company, Pfizer Inc., Teva Canada Limited (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global retinoblastoma treatment market performed so far and how will it perform in the coming years ?
  • What are the drivers, restraints, and opportunities in the global retinoblastoma treatment market ?
  • What are the key regional markets ?
  • Which countries represent the most attractive retinoblastoma treatment markets ?
  • What is the breakup of the market based on the type ?
  • What is the breakup of the market based on the treatment type ?
  • What is the breakup of the market based on the type of staging ?
  • What is the breakup of the market based on application ?
  • What is the competitive structure of the global retinoblastoma treatment market ?
  • Who are the key players/companies in the global retinoblastoma treatment market ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Retinoblastoma Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Non-Hereditary Retinoblastoma
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hereditary Retinoblastoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Surgery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiation Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Laser Therapy (Photocoagulation)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cryotherapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Thermotherapy
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Chemotherapy
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Opthalmic Artery Infusion Chemotherapy
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 High-Dose Chemotherapy and Stem Cell Transplant
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Type of Staging

  • 8.1 Intraocular Retinoblastoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Extraocular Retinoblastoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Cancer Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bristol Myers Squibb Company
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Pfizer Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Teva Canada Limited (Teva Pharmaceutical Industries Ltd.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report